Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;18(22):2383-2392.
doi: 10.2217/fon-2022-0358. Epub 2022 Jun 13.

ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast

Elisa Agostinetto  1   2 , Guilherme Nader-Marta  1 , Marianne Paesmans  1 , Lieveke Ameye  1 , Isabelle Veys  1 , Laurence Buisseret  1 , Patrick Neven  3 , Donatienne Taylor  4 , Christel Fontaine  5 , Francois P Duhoux  6 , Jean-Luc Canon  7 , Hannelore Denys  8 , Florence Coussy  9 , Camille Chakiba  10 , Joana Mourato Ribeiro  11 , Martine Piccart  1 , Christine Desmedt  12 , Michail Ignatiadis  1 , Philippe Aftimos  1
Affiliations
Review

ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast

Elisa Agostinetto et al. Future Oncol. 2022 Jul.

Abstract

Invasive lobular carcinoma (ILC) is the most common histologic subtype of breast cancer after invasive ductal carcinoma (i.e., no special type [NST]). ILC differs from NST in clinical presentation, site-specific metastases and response to conventional therapies. Loss of E-cadherin protein expression, due to alterations in its encoding gene CDH1, is the most frequent oncogenic event in ILC. Synthetic lethality approaches have shown promising antitumor effects of ROS1 inhibitors in models of E-cadherin-defective breast cancer in in vivo studies and provide the rationale for testing their clinical activity in patients with ILC. Entrectinib is a tyrosine kinase inhibitor targeting TRK, ROS1 and ALK tyrosine kinases. Here, the authors present ROSALINE (NCT04551495), a phase II study testing neoadjuvant entrectinib and endocrine therapy in women with estrogen receptor-positive, HER2-negative early ILC.

Keywords: ROS1; breast cancer; entrectinib; lobular; neoadjuvant.

Plain language summary

Breast cancer is the most common cancer among women worldwide. Breast cancer is not a unique disease, but rather a heterogeneous disease, with different subtypes. Lobular breast cancer is the second most common histologic subtype of breast cancer after ductal breast cancer. Lobular breast cancer has some peculiar characteristics that make it a distinct entity in the context of breast cancer. Nevertheless, few clinical studies so far have focused specifically on this subtype. ROSALINE is a clinical study aimed to test entrectinib, a new drug that showed promising activity in preliminary research studies, in combination with endocrine therapy in women with lobular breast cancer before surgery. Trial Registration Number: NCT04551495 (ClinicalTrials.gov).

PubMed Disclaimer

Associated data